These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36010354)

  • 21. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
    Lan Y; Liu D; Lin M
    Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Sharma G; Sharma A; Krishna M; Devana SK; Singh SK
    Urol Oncol; 2022 Apr; 40(4):163.e1-163.e9. PubMed ID: 34535354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
    Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
    Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.
    Rodrigues Pessoa R; Mueller AC; Boxley P; Flaig TW; Piper C; Konety B; Yu JB; Gershman B; Kukreja J; Kim SP
    Urol Oncol; 2021 Nov; 39(11):786.e1-786.e8. PubMed ID: 33846085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.
    Du J; Wang SH; Yang Q; Chen QQ; Yao X
    World J Surg Oncol; 2016 Apr; 14():137. PubMed ID: 27129876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
    J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
    Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
    Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer.
    Deng T; Liu B; Duan X; Zhang T; Cai C; Zeng G
    Sci Rep; 2017 Jun; 7(1):3172. PubMed ID: 28600516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.
    Lee LJ; Kwon CS; Forsythe A; Mamolo CM; Masters ET; Jacobs IA
    Clinicoecon Outcomes Res; 2020; 12():693-709. PubMed ID: 33262624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis.
    Ye Z; Chen J; Hong Y; Xin W; Yang S; Rao Y
    Onco Targets Ther; 2018; 11():4641-4649. PubMed ID: 30122955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis.
    Pan J; Liu M; Zhou X
    Front Med; 2014 Jun; 8(2):241-9. PubMed ID: 24810644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.
    Soria F; Droller MJ; Lotan Y; Gontero P; D'Andrea D; Gust KM; Rouprêt M; Babjuk M; Palou J; Shariat SF
    World J Urol; 2018 Dec; 36(12):1981-1995. PubMed ID: 29931526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.